Roberta Zappasodi
Cornell University · 233 works · 18,308 citations · h-index 38
Top works
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- B cells and tertiary lymphoid structures promote immunotherapy response
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
- Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
- A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death
- CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
- Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- Rational design of anti-GITR-based combination immunotherapy
- Non-conventional Inhibitory CD4+Foxp3–PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
- Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
- Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- Modulating Treg stability to improve cancer immunotherapy
- Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab